Kissei Introduces Analysis and Preparative Purification Platform for Small Molecules

Kissei Pharmaceutical Co., Ltd. (Head Office: Matsumoto, Nagano; Chairman and CEO: Mutsuo Kanzawa, "Kissei") has introduced analysis and preparative purification platform for small molecules from ChromaJean Co., Ltd. (Head Office: Fujisawa, Kanagawa; President and CEO: Katsuhiko Miwa; "ChromaJean").

This platform is an innovative platform that systematizes the purification process of small molecules using chromatography, through "Jeanious One LC," ChromaJean's proprietary support solution for in-house chromatographic processes. By introducing this platform, we will advance standardization, labor-saving, acceleration, and depersonalization of the purification process, significantly reducing the human resources, costs, and time required for this process. Additionally, the resources saved will be reallocated to more creative tasks, thereby enhancing the productivity of drug discovery research.

"We are committed to enhancing the productivity of drug discovery research in order to accelerate the discovery of innovative small molecule drugs. The introduction of this platform will automate the purification process of synthetic compounds, allowing our medicinal chemists to focus on the creative research in which they should truly engage. We are very pleased that this platform will enable us to create innovative new drug candidates in a shorter period and strengthen our novel product pipeline." said Mutsuo Kanzawa, CEO of Kissei.

"We are very pleased to introduce our analysis and preparative purification platform for small molecules to Kissei's drug discovery research sites. This platform provides a proprietary systematized analysis and preparative purification process for liquid chromatography that enables anyone to obtain the same results anytime, anywhere. We are confident that the analysis and preparative purification process, which does not depend on the experience and intuition of expert researchers, will contribute to accelerating Kissei's drug discovery research." said Katsuhiko Miwa, CEO of ChromaJean.

As an R&D-oriented pharmaceutical company, Kissei Pharmaceutical is striving to advance our technologies to accelerate and enhance the quality of drug discovery research with the aim of creating highly innovative and useful new drugs.

《 Reference 》

About ChromaJean Co., Ltd.
ChromaJean Co., Ltd. is a specialist in analysis and separation using chromatography methods. By systematizing chromatographic processes, we realize chromatography technology where "not struggling is the norm," contributing to the research and development of pharmaceuticals and functional materials.
https://chromajean.com/

About Chromatography
A technique for separating and purifying substances. By combining a mobile phase (gas, liquid, or supercritical fluid) with a stationary phase (a tube called a column), substances are separated and purified from a mixture of multiple substances by utilizing differences in size, mass, and physical properties.